Ozempic.Getty ImagesThe US economy will see a surge in growth as more people start to take GLP-1 weight loss drugs.Goldman Sachs forecasted that US GDP would jump by 1% if 60 million Americans took a GLP-1 drug."The main reason we see economic upside from healthcare innovation is that poor health imposes significant economic costs," Goldman Sachs said.The more people that take GLP-1 weight loss drugs, the faster the US economy will grow, according to estimates from Goldman Sachs.The bank said in a note on Thursday that US GDP would grow by an extra 1% if 60 million Americans took GLP-1 drugs by 2028.The thinking behind Goldman's forecast is that poor health is a burden for economic growth, as it can weigh heavily on the total labor supply and total hours worked through elevated "missed days" at work, early death, and informal caregiving that takes people out of the workforce."Combining current losses in hours worked and labor force participation from sickness and disability, early deaths, and informal caregiving, we estimate that GDP would potentially be over 10% higher if poor health outcomes did not limit labor supply in the US," Goldman Sachs economist Jan Hatzius said.So, a drug that has shown great promise in improving a wide range of health outcomes for patients could ultimately have a sizable impact on the broader economy."The main reason we see meaningful upside from healthcare innovation is that poor health imposes significant economic costs.